Evidence map›Paper›PMID 36199951›Full record

ArticleJournal of contemporary brachytherapy2022

An Asian multi-national, multi-institutional, retrospective study on image-guided brachytherapy in cervical adenocarcinoma and adenosquamous carcinoma.

Noriyuki Okonogi, Naoya Murakami, Ken Ando, Masumi Murata, Kazutoshi Murata, Tomomi Aoshika, Shingo Kato, Anneyuko I Saito, Joo-Young Kim, Yasuo Yoshioka and 16 more

Open access · goldAbstract read
In one paragraph

Article in Journal of contemporary brachytherapy, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 1 pooled it
1.3field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 1 synthesis or guideline pooled it, 7 citations in OpenAlex.

  1. Association between Silva pattern-based classification and endocervical adenocarcinoma: a systematic review and meta-analysis.International journal of gynecological cancer : official journal of the International Gynecological Cancer Society · 2024
    Pooled it
  2. Article
  3. Article
  4. Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

26 authors at 4 institutions in 1 country.

Noriyuki Okonogi *QST Hospital, National Institutes for Quantum Science and Technology, Inage-ku, Chiba City, Chiba, Japan.
Naoya Murakami *Department of Radiation Oncology, National Cancer Center Hospital, Chuo-ku, Tokyo, Japan.
Ken Ando *Department of Radiation Oncology, Gunma Prefectural Cancer Center, Ota City, Gunma, Japan.
Masumi Murata *Department of Radiation Oncology, Gunma Prefectural Cancer Center, Ota City, Gunma, Japan.
Kazutoshi Murata *QST Hospital, National Institutes for Quantum Science and Technology, Inage-ku, Chiba City, Chiba, Japan.
Tomomi Aoshika *Department of Radiation Oncology, Saitama Medical University International Medical Center, Hidaka City, Saitama, Japan.
Shingo Kato *Department of Radiation Oncology, Saitama Medical University International Medical Center, Hidaka City, Saitama, Japan.
Anneyuko I Saito *Department of Radiation Oncology, Juntendo University Faculty of Medicine, Tokyo, Japan.
Joo-Young Kim *Department of Radiation Oncology, National Cancer Center, Ilsandong, Goyang Gyeonggi, Korea.
Yasuo Yoshioka *Radiation Oncology Department, Cancer Institute Hospital of Japanese Foundation for Cancer Research, Koto-ku, Tokyo, Japan.
Shuhei Sekii *Department of Radiation Oncology, Hyogo Cancer Center, Akashi City, Hyogo, Japan.
Kayoko Tsujino *Department of Radiation Oncology, Hyogo Cancer Center, Akashi City, Hyogo, Japan.
Chairat Lowanichkiattikul *Division of Radiation Oncology, Department of Radiology, Faculty of Medicine, Ramathibodi Hospital, Mahidol University, Rajataewe, Bangkok, Thailand.
Poompis Pattaranutaporn *Division of Radiation Oncology, Department of Radiology, Faculty of Medicine, Ramathibodi Hospital, Mahidol University, Rajataewe, Bangkok, Thailand.
Yuko Kaneyasu *Department of Radiation Oncology, National Hospital Organization Fukuyama Medical Center, Fukuyama City, Hiroshima, Japan.
Tomio Nakagawa *Department of Radiation Oncology, National Hospital Organization Fukuyama Medical Center, Fukuyama City, Hiroshima, Japan.
Miho Watanabe *Department of Radiology, Chiba University Hospital, Chuo-ku, Chiba City, Chiba, Japan.
Takashi Uno *Department of Radiology, Chiba University Hospital, Chuo-ku, Chiba City, Chiba, Japan.
Rei Umezawa *Department of Radiation Oncology, Tohoku University Graduate School of Medicine, Aoba-ku, Sendai, Miyagi, Japan.
Keiichi Jingu *Department of Radiation Oncology, Tohoku University Graduate School of Medicine, Aoba-ku, Sendai, Miyagi, Japan.
Ayae Kanemoto *Department of Radiation Oncology, Niigata Cancer Center Hospital, Niigata, Japan.
Masaru Wakatsuki *QST Hospital, National Institutes for Quantum Science and Technology, Inage-ku, Chiba City, Chiba, Japan.
Katsuyuki Shirai *Department of Radiology, Jichi Medical University Hospital, Shimotsuke City, Tochigi, Japan.
Hiroshi Igaki *Department of Radiation Oncology, National Cancer Center Hospital, Chuo-ku, Tokyo, Japan.
Tatsuya Ohno *Department of Radiation Oncology, Gunma University Graduate School of Medicine, Maebashi City, Gunma, Japan.
Jun Itami *Department of Radiation Oncology, National Cancer Center Hospital, Chuo-ku, Tokyo, Japan.
National Cancer Center Hospital East · JPNational Institutes for Quantum and Radiological Science and Technology · JPJuntendo University · JPNiigata Cancer Center Hospital · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Purpose: There are limited reports on outcomes of three-dimensional image-guided brachytherapy (3D-IGBT) for cervical adenocarcinoma in Asia. In a multi-institutional retrospective study, we assessed the clinical outcomes of three-dimensional image-guided brachytherapy for cervical adenocarcinoma or adenosquamous carcinoma (CA/CAC) in Asian countries. Material and methods: Patients who had undergone definitive radiation therapy/concurrent chemoradiotherapy for untreated cervical cancer between 2000 and 2016 were registered. Those who had undergone 3D-IGBT for histologically proven CA/CAC were included. Data on patients' characteristics and treatment were collected, including tumor reduction rate (defined as a percentage of reduction in tumor size before brachytherapy compared with that at diagnosis) and high-risk clinical target volume D Results: Anonymized data of 498 patients were collected. Of the 498 patients, 36 patients met inclusion criteria. The median follow-up period was 39 months. The 3-year OS, LC, and PFS rates were 68.4%, 68.5%, and 44.4%, respectively. After treatment, five patients had tumor re-growth without complete disappearance of the tumor. Two patients developed grade 3 vaginal toxicity or grade 4 rectal toxicity; none developed other severe late toxicities. A tumor reduction rate of > 26.3% was the only significant factor in multivariate analyses, and was associated with significantly better OS ( Conclusions: LC rate of CA/CAC was insufficient despite 3D-IGBT. Meanwhile, tumor reduction rate was associated with LC, OS, and PFS rates. Therefore, CA/CAC may require a different treatment strategy than that applied in cervical squamous cell carcinoma.

Indexed as

brachytherapychemoradiotherapyradiotherapyuterine cervical neoplasms

Identifiers

PMID36199951
PMCPMC9528827
OpenAlexW4295918746

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-SA
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.